Risk factors for ductal and lobular breast cancer: results from the nurses' health study

被引:55
作者
Kotsopoulos, Joanne [1 ,2 ]
Chen, Wendy Y. [1 ,2 ,3 ]
Gates, Margaret A. [1 ,2 ,4 ]
Tworoger, Shelley S. [1 ,2 ,4 ]
Hankinson, Susan E. [1 ,2 ,4 ]
Rosner, Bernard A. [1 ,2 ,5 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[4] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
关键词
MENOPAUSAL HORMONE-THERAPY; DIFFERENT HISTOLOGIC TYPES; WOMEN; 65-79; YEARS; REPRODUCTIVE FACTORS; ANTHROPOMETRIC FACTORS; REPLACEMENT THERAPY; RECEPTOR STATUS; IN-SITU; CARCINOMA; EXPRESSION;
D O I
10.1186/bcr2790
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Ductal and lobular carcinomas are the two most common types of invasive breast cancer. Whether well-established risk factors are differentially associated with risk on the basis of histologic subtype is not clear. We prospectively investigated the association between a number of hormonal and nonhormonal exposures and risk defined by histologic subtype among 4,655 ductal and 659 lobular cases of postmenopausal breast cancer from the Nurses' Health Study. Methods: Multivariate Cox proportional hazards regression stratified by histologic subtype and time period was used to examine the association between risk factors and the incidence of ductal and lobular subtypes. For each exposure, we calculated the P value for heterogeneity using a likelihood ratio test comparing models with separate estimates for the two subtypes versus a single estimate across subtypes. Results: The associations with age at menarche (P-heterogeneity (het) = 0.03), age at first birth (P-het < 0.001) and postmenopausal hormone use (P-het < 0.001) were more strongly associated with lobular cancers. The associations with age, nulliparity, parity, age at menopause, type of menopause, alcohol intake, adult body mass index (BMI), BMI at age 18, family history of breast cancer and personal history of benign breast disease did not vary by subtype (P-het >= 0.08). Results were similar when we restricted the analyses to estrogen receptor-positive and progesterone receptor-positive tumors. Conclusions: These data indicate that breast cancer is a heterogeneous disease, and the differential association with a number of risk factors is suggestive of etiologically distinct tumors. Epidemiological analyses should continue to take into account a modifying role of histology.
引用
收藏
页数:11
相关论文
共 48 条
  • [1] Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome
    Arpino, G
    Bardou, VJ
    Clark, GM
    Elledge, RM
    [J]. BREAST CANCER RESEARCH, 2004, 6 (03): : R149 - R156
  • [2] Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition
    Bakken, Kjersti
    Fournier, Agnes
    Lund, Eiliv
    Waaseth, Marit
    Dumeaux, Vanessa
    Clavel-Chapelon, Francoise
    Fabre, Alban
    Hemon, Bertrand
    Rinaldi, Sabina
    Chajes, Veronique
    Slimani, Nadia
    Allen, Naomi E.
    Reeves, Gillian K.
    Bingham, Sheila
    Khaw, Kay-Tee
    Olsen, Anja
    Tjonneland, Anne
    Rodriguez, Laudina
    Sanchez, Maria-Jose
    Amiano Etxezarreta, Pilar
    Ardanaz, Eva
    Tormo, Maria-Jose
    Peeters, Petra H.
    van Gils, Carla H.
    Steffen, Annika
    Schulz, Mandy
    Chang-Claude, Jenny
    Kaaks, Rudolf
    Tumino, Rosario
    Gallo, Valentina
    Norat, Teresa
    Riboli, Elio
    Panico, Salvatore
    Masala, Giovanna
    Gonzalez, Carlos A.
    Berrino, Franco
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (01) : 144 - 156
  • [3] Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0
  • [4] Epidemiology of endocrine-related risk factors for breast cancer
    Bernstein, L
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2002, 7 (01) : 3 - 15
  • [5] Menopausal Hormone Therapy and Breast Cancer Risk in the NIH-AARP Diet and Health Study Cohort
    Brinton, Louise A.
    Richesson, Douglas
    Leitzmann, Michael F.
    Gierach, Gretchen L.
    Schatzkin, Arthur
    Mouw, Traci
    Hollenbeck, Albert R.
    Lacey, James V., Jr.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (11) : 3150 - 3160
  • [6] Postmenopausal Hormone Use and Breast Cancer Associations Differ by Hormone Regimen and Histologic Subtype
    Calle, Eugenia E.
    Feigelson, Heather Spencer
    Hildebrand, Janet S.
    Teras, Lauren R.
    Thun, Michael J.
    Rodriguez, Carmen
    [J]. CANCER, 2009, 115 (05) : 936 - 945
  • [7] Hormone replacement therapy in relation to breast cancer
    Chen, CL
    Weiss, NS
    Newcomb, P
    Barlow, WN
    White, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (06): : 734 - 741
  • [8] Clarke Christina A, 2006, J Clin Oncol, V24, pe49, DOI 10.1200/JCO.2006.08.6504
  • [9] Cumulative number of menstrual cycles and breast cancer risk: results from the E3N cohort study of French women
    Clavel-Chapelon, F
    [J]. CANCER CAUSES & CONTROL, 2002, 13 (09) : 831 - 838
  • [10] Cocquyt V, 2005, CURR OPIN OBSTET GYN, V17, P55